A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms FAVOR Flu
  • Sponsors FujiFilm Pharmaceuticals USA; MDVI
  • Most Recent Events

    • 25 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Feb 2015 Status changed from recruiting to active, no longer recruiting, as reported in the MediVector media release.
    • 17 Feb 2015 According to MediVector media release, data from this and another phase III trial will be used in the application for marketing approval for favipiravir in the USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top